velfærd vinge hjemmehørende nature medicine brief communication glas faldskærm ekstremt
Antibody responses to SARS-CoV-2 in patients with COVID-19
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma | Nature Medicine
Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19 | Nature Medicine
SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes | Nature Medicine
Real-time tracking of self-reported symptoms to predict potential COVID-19 | Nature Medicine
Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy | Nature Medicine
Mpox
Brief Communications in 2020 | Nature Medicine
Pilot study of responsive nucleus accumbens deep brain stimulation for loss-of-control eating | Nature Medicine
efficacy face mask covid 19 nature medicine
A serological assay to detect SARS-CoV-2 seroconversion in humans | Nature Medicine
Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination | Nature Medicine
A serological assay to detect SARS-CoV-2 seroconversion in humans
Nature Medicine
Brief Communications in 2020 | Nature Medicine
Hemolysis contributes to anemia during long-duration space flight | Nature Medicine
目次 | Nature Medicine | Nature Portfolio
Temporal dynamics in viral shedding and transmissibility of COVID-19 | Nature Medicine
Brief Communications in 2021 | Nature Medicine
Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera | Nature Medicine
Brief Communications in 2021 | Nature Medicine
SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes | Nature Medicine
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2 | Nature Medicine
Countries Primarily Using CoronaVac Vaccines Should Consider mRNA Vaccine Boosters to face Omicron